Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Udine – page 14

244 clinical trials in Udine, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Udine at a glance
244
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

244 trials in Udine

Open in trial search

Plasma cell myeloma

Not recruiting

Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Fondazione European Myeloma Network Italy O.N.L.U.S.

Idiopathic inflammatory myopathy

Not recruiting

Study on the Effects and Safety of Efgartigimod PH20 SC for Adults with Active Idiopathic Inflammatory Myopathy

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Acute myeloid leukaemia+10

Not recruiting

Long-Term Access to Ibrutinib for Patients with Lymphoma, Leukemia, and Other Conditions

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

K-ras gene mutation+2

Not recruiting

Study Comparing Divarasib, Sotorasib, and Adagrasib for Patients with Advanced or Metastatic KRAS G12C-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Mantle cell lymphoma

Not recruiting

Study on Rituximab, Bendamustine, Cytarabine, and Venetoclax for High-Risk Elderly Patients with Mantle Cell Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Fondazione Italiana Linfomi Ets

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Trastuzumab Deruxtecan with Chemotherapy for Patients with HER2-Low, Hormone Receptor Positive Breast Cancer After Endocrine Therapy Progression

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Neovascular age-related macular degeneration

Not recruiting

Study on the Effectiveness of OPT-302 and Ranibizumab for Patients with Wet Age-related Macular Degeneration

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab
  • Sponsor:Opthea Limited

Colorectal cancer metastatic

Not recruiting

Study Comparing Panitumumab and Regorafenib Sequence for Patients with Metastatic Colorectal Cancer Resistant to Previous Treatments

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Panitumumab
  • Sponsor:Fondazione GONO G.I.

Colorectal cancer metastatic+1

Not recruiting

Study on the Safety and Effectiveness of Trifluridine/Tipiracil, Capecitabine, and Bevacizumab for Patients with Metastatic Colorectal Cancer Unfit for Intensive Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Fondazione GONO G.I.

Malignant melanoma

Not recruiting

Study Comparing Naporafenib and Trametinib Combination to Other Therapies for Patients with Previously Treated Unresectable or Metastatic NRAS Mutant Melanoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine
  • Sponsor:Erasca Inc.

Dry age-related macular degeneration

Not recruiting

Study on Elamipretide for Patients with Dry Age-Related Macular Degeneration (Dry AMD)

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Elamipretide Trihydrochloride
  • Sponsor:Stealth Biotherapeutics Inc.

Study of Buparlisib and Paclitaxel for Patients with Recurrent or Metastatic Head and Neck Cancer

Not recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Buparlisib
  • Sponsor:Adlai Nortye USA Inc.

Other cities in Italy

The busiest research cities in the country

All 234 cities in Italy

Clinical research in Udine

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials investigating treatments for various cancer types, including leukemia, gastric cancer, and multiple myeloma. Studies focus on targeted therapies and immunotherapy approaches.

  • Chronic Myeloid Leukemia Treatment
  • Gastroesophageal Cancer Therapy
  • Advanced Pancreatic Cancer Management

Research emphasizes personalized treatment approaches and combination therapies to improve patient outcomes.

02 Autoimmune Conditions

Studies examining new therapeutic options for inflammatory and autoimmune disorders, with particular focus on psoriatic arthritis and Sjögren's Syndrome.

  • Biomarker Analysis in Psoriatic Arthritis
  • Novel Treatments for Inflammatory Conditions
  • Long-term Disease Management

Trials aim to evaluate both safety and efficacy of innovative biological treatments.

03 Cardiovascular Studies

Research focusing on heart health and prevention, including studies of heart failure prevention and treatment of recurrent pericarditis.

  • Heart Failure Prevention Strategies
  • Pericarditis Treatment Innovation
  • Cardiovascular Risk Management

Investigations center on both preventive approaches and therapeutic interventions.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.